Antibody discovery has never been more challenging, or more complicated. The targets are harder, the timelines are tighter, and the pressure to move the right molecule forward is immense.
MindWalk provides antibody discovery and development lab services for complex targets, difficult epitopes, and biologics programs that require more than standard screening. Our teams support therapeutic antibody discovery, anti-idiotype antibody development, diagnostic antibody generation, functional screening, recombinant antibody production, and candidate characterization across multiple discovery platforms.
MindWalk operates across AI, Data, and Lab solutions. For antibody discovery and development programs, those capabilities can be offered individually or combined in the way the program requires. Some teams come to MindWalk for wet lab execution. Others need biological data infrastructure, AI-enabled analysis, or a custom combination of capabilities across all three.
MindWalk calls this flexible operating model the BioIntelligence Ecosystem.
MindWalk discovery programs have supported more than 20 client-owned molecules that advanced to clinic, including programs involving challenging target classes, complex antibody formats, and difficult development requirements.
Your team will work 1:1 with our scientific and technology experts at every stage of biologics discovery and development, from target analysis through protein production and characterization. MindWalk supports antibody discovery and development across therapeutic, anti-idiotype, and diagnostic applications, offering custom programs tailored to the biology and requirements of your specific research needs.
The MindWalk BioIntelligence Ecosystem is a strategic combination of three disciplines, artificial intelligence, multimodal data infrastructure, and advanced wet lab research, customizable to the specific antibody discovery and development needs of your program. It is not a fixed pipeline applied uniformly, but a system built to adapt: to your target class, your assay requirements, your development stage, and your unique challenge.
Discovery is no longer a single-discipline endeavor. The programs that advance are the ones where biology, data, and technology are working around the same objective, instead of being handed off sequentially between them. In practice, this means the experimental design informs the data strategy, the data strategy shapes the analytical framework, and the analytical outputs feed back into the next experimental decision. Each discipline calibrated to the others in real time.
Conventional immunization and screening platforms can deliver results within a defined range of antigen classes. Outside that range, complex targets such as multi-transmembrane proteins with minimal extracellular epitope exposure, antigens with high sequence homology to host proteins, conformationally dynamic or occluded epitopes, or cytokines embedded in redundant signaling networks present unique challenges that can delay discovery efforts. Applying the standard approaches to these complex targets often yields poor response rates, low repertoire diversity against the relevant epitope, or hits that don't translate to functional activity.
These target classes require deliberate platform design: immunization strategies that break tolerance or present native conformation, screening systems that capture rare B cell clones with the right specificity, and functional filters applied early enough to matter. The MindWalk BioIntelligence Ecosystem was built around exactly this requirement—and the programs that have advanced to the clinic through our platform include challenging target classes such as GPCRs, ion channels, highly conserved antigens, and tolerogenic self-antigens.
MindWalk operates multiple antibody discovery platforms, including B cell Select®, hybridoma, and yeast display. As a recognized global leader1 in antibody discovery lab services, MindWalk brings platform breadth, and program-specific strategy to complex discovery and development work.
Across its discovery platforms, MindWalk programs have supported antibody candidates that advanced to the clinic, including candidates discovered through both B cell Select® and hybridoma workflows.
Platform selection is determined by the biology of the target and the requirements of the program: therapeutic, research reagent, anti-drug or anti-idiotypic, diagnostic, or engineered biologics application. The right platform is a multi-parameter scientific decision made at the outset of engagement, not a default workflow applied uniformly.
Where a single program requires molecules for multiple purposes, such as therapeutic candidate discovery and paired anti-idiotype reagents for downstream pharmacokinetic studies, MindWalk can design combined discovery packages to streamline logistics and stage outcomes.
Throughout discovery programs, data generated at the bench flows into the LensAI™ platform powered by HYFT Technology, where sequencing outputs, functional readouts, kinetic profiles, and supporting program data are processed as a unified candidate profile. This gives teams a connected view of candidate performance as program results are delivered.
Across technologies, MindWalk applies a function-first philosophy. The unique biology, structural architecture, and mechanistic behavior of a target inform program strategy and screening approach from the beginning. Discovery workflows are designed to introduce relevant binding and functional assessments early, so candidate selection is based on more than antigen reactivity alone.
Custom functional assays can be built into programs from inception, including receptor blockade experiments, internalization assessments, effector function studies, and other mechanism-relevant readouts. The goal is to uncover candidate behavior early enough for those findings to shape the program.
MindWalk’s proprietary B cell Select® platform is a core antibody discovery technology behind its antibody discovery lab offering, built around the exceptional immune biology of the rabbit host. When paired with the rabbit immune system, B cell Select® has achieved a >98% antibody discovery success rate across defined discovery programs to date.2 This figure reflects both the unique biological properties of the rabbit and the depth of functional screening built into the workflow.
Unlike murine systems, rabbits generate hyperdiverse CDR-H3 and CDR-L3 loops through gene conversion and somatic hypermutation, effectively expanding the specificity space available for epitope engagement. This architecture is particularly well suited to conformational and cryptic epitopes on human targets with high sequence conservation that may fail to generate useful responses in conventional murine platforms. The workflow combines antigen-specific memory B cell enrichment with early-stage functional validation and identification of native heavy and light chain sequence pairs. Clonal diversity is captured alongside mechanistic insight within the same experimental tier, not as part of a downstream reconciliation step. Target-reactive primary B cell supernatants are generated, screened, and made accessible early in the workflow, allowing for function-first candidate prioritization and deeper mechanistic interrogation.
Additional species beyond rabbit are available.
The rise of bispecific antibodies, multispecific therapeutics, and CAR-T cell therapies created a molecular engineering problem that conventional IgG formats are not always built to solve. Assembling two or more binding specificities into a single functional molecule requires modular building blocks that are small, stable, independently foldable, and adaptable to functions full-length antibodies do not naturally possess.
VHH single-domain antibodies, derived from the heavy-chain antibodies of the camelid immune system, are increasingly recognized as ideal building blocks for that challenge. MindWalk developed B cell Llama™ because the era demanded a platform purpose-built for it.
B cell Llama™ extends the B cell Select® workflow to camelids by using the same function-first enrichment approach to isolate target-reactive B cells directly from immunized llamas. These enriched B cells are critical to identifying VHH antibodies developed in a naturally matured immune repertoire, providing sequence diversity and functional quality that synthetic display libraries may not fully capture and genetically constrained transgenic platforms may limit.
The camelid immune system generates VHH domains with extended CDR-H3 loops capable of engaging epitope geometries that may be inaccessible to conventional IgG formats, including enzyme active sites, receptor clefts, and conserved regions occluded by glycan shielding or adjacent structural elements.
Peer-reviewed research informing the platform has demonstrated advantages that go beyond epitope access. In the reported study, VHH antibodies displayed in multivalent formats achieved sub-nanomolar potency, 10- to 25-fold greater than the same antibodies in monovalent form.³ A trivalent VHH construct neutralized variants that escaped monovalent formats and two approved antibody therapies, demonstrating how rational reassembly of the same building block can restore activity in a defined experimental context.
LensAI™ is designed to support this process by guiding immunogen design before immunization, evaluating candidates based on predicted functionality, and modeling multispecific constructs in silico before laboratory synthesis begins.
MindWalk’s hybridoma platform is a well-established path for monoclonal antibody discovery across therapeutic, diagnostic, and reagent applications. Hybridoma remains a proven and reliable option for teams with existing hybridoma-centric workflows or specific program requirements that align with the technology. Hybridoma technology can be especially useful for challenging targets such as tumor cell-specific surface markers or receptors that cannot be presented outside the context of the cell. The target-flexible nature of the platform enables discovery of antibodies with unique specificity and function that may not be identifiable through approaches dependent on purified or recombinant antigen formats.
As with MindWalk’s B cell Select® programs, clone selection is not based on antigen reactivity assessment alone. Hybridoma panels are screened against mechanism-relevant functional criteria alongside binding performance, helping ensure that quality standards built into the discovery campaign carry through to the final deliverables. MindWalk offers hybridoma and B cell Select® as stand-alone and complementary discovery options. The right platform, or combination of platforms, is determined by your program’s unique functional, analytical, and production requirements, and MindWalk’s expert team is experienced in helping clients make that determination.
Yeast display technology is deployed for identification of clones from immune sources as well as from in silico-designed synthetic libraries for engineering and optimization of a pre-existing antibody or for screening of de novo-designed functional binders. Yeast, with its eukaryotic machinery, has been demonstrated to be able to express antibody fragments extremely efficiently, a feature that distinguishes itself from the prokaryotic-based phage display platform. In addition, the FACS-driven screening that is at the core of the yeast display platform enables enrichment and selection of clones based on binding affinity (both high and low) as well as expression level. The streamlined, downstream conversion of the clones selected through multiple rounds of yeast display and screening is fully customized for each program in order to achieve the intended output as rapidly as possible. If a unique and challenging functionality that can only be achieved through affinity-based selection or affinity tuning, or a complex and multiparametric engineering design requires screening of a library of variants, we have the solution in yeast display technology capability.
Successful antibody discovery programs require sensitive and selective screening approaches to identify best-fit clones for each program’s specific needs.
MindWalk’s lead discovery platforms are supported by broad antibody screening and characterization capabilities that enable data-driven decisions from the earliest stages of a project. Standard discovery programs can include indirect ELISA screening with the option to screen across multiple antigens. When programs demand more specialized screening, MindWalk works with client teams to develop custom assays, including target-specific sandwich ELISA, competitive ELISA, and blot-based experiments using automated western blot systems.
In addition to traditional antibody screening methods, MindWalk offers specialized cell-based and biochemical antibody screening and characterization approaches. Our facilities include advanced flow cytometry capabilities to support target identification and antibody assessment across transmembrane, secreted, and intracellular targets using stable or transfected cell lines. With high-throughput flow screening instrumentation, MindWalk’s team can design and establish custom workflows for cell-based analysis across discovery stages, from test bleed to B cell supernatant to recombinant clone evaluation.
Using its bio-layer interferometry (BLI) platform, MindWalk’s protein science team can introduce kinetic and binding assessments as early as the B cell supernatant stage when appropriate. Clones can be ranked by relative off-rate against soluble targets or organized into functional bins based on competitive binding assessments. At the recombinant antibody development stage, full kinetic analysis can be performed on the BLI platform to produce binding information needed for confident candidate comparison.
Function-first discovery means these assessments are not treated as downstream confirmation only. They are used to shape the program while there is still time to change what happens next.
MindWalk supports therapeutic antibody discovery and development across oncology, infectious disease, neurodegeneration, metabolic disease, inflammation, rare disease, and other challenging and novel therapeutic areas. Our teams work across target types, with particular experience in complex target classes, difficult epitopes, layered or highly regulated mechanisms, and therapeutic formats that have resisted conventional approaches. Our genetic immunization approaches are available across species and platform—enabling the discovery and prioritization of conformationally relevant drug candidates against historically difficult transmembrane targets including GPCRs and ion channels.
Our platform addresses biological complexity end-to-end, combining advanced discovery workflows with insights from the LensAI™ platform to connect sequence, structure, function, developability, immunogenicity, and literature context earlier in the discovery process. This helps teams prioritize candidates not only by binding, but by functional potential, downstream format fit, and translational relevance. Over 20 client-owned molecules have advanced to clinical trials across complex and challenging programs spanning these therapeutic areas.
Our approach to drug discovery is especially well suited to complex programs, including novel targets, difficult epitopes, challenging mechanisms, multispecific formats, and programs with limited biological precedent. By combining deep discovery expertise with LensAI™ enabled analysis, we help partners move from candidate generation to candidate understanding earlier, helping reduce reliance on affinity-first selection and enabling more informed decisions before costly downstream development.
The quality of your therapeutic program’s critical anti-idiotype reagents is not a secondary concern, it can become a rate-limiting factor in pre-clinical bioanalytical method development. Anti-idiotypic antibodies (anti-IDs) serve as critical reagents and positive control that your pharmacokinetic (PK), anti-drug antibody (ADA), and receptor occupancy assays are built around. If an anti-ID is poorly characterized, has wrong epitope specificity, lacks sufficient affinity, or does not fit the intended assay format, the downstream method may fail validation, produce unreliable clinical data, or require costly reagent regeneration and assay redevelopment.
MindWalk’s anti-ID discovery program has achieved a 100% discovery success rate4 across completed programs to date and generates clones with defined epitope specificity, including anti-paratope, anti-framework, and anti-combining site antibodies. Clone selection is guided by the intended assay format and analytical requirements. Anti-IDs are characterized and paired for use across assay formats that anchor clinical bioanalysis: ligand-binding assays in bridging ELISA, electrochemiluminescence-based platforms for highly sensitive ADA and PK quantification, SPR-based confirmatory assays, and cell-based receptor occupancy formats where free drug quantification is required.
For therapeutic antibodies with complex formats, bispecifics, ADCs, Fc-fusion proteins, we design immunization and screening strategy in collaboration with your bioanalytical team around your specific assay architecture and submission context. Reagent characterization includes epitope binning relative to the therapeutic's CDR and framework regions, affinity determination, and drug-tolerance profiling where assay design requires it.
MindWalk’s ADA and bioanalytical reagent discovery capabilities support a broad range of drug formats, including biologics, small molecules, peptides, and conjugated payloads. The same assay-aware approach that drives our anti-idiotypic programs can be applied across these drug formats to generate high-specificity critical reagents aligned with your drug development program’s analytical requirements.
Diagnostic antibody discovery requires antibodies that are fit for the intended assay, sample type, and cross-reactivity profile. Detection reagents must demonstrate exceptional specificity and sensitivity to distinguish closely related molecules and identify rare or low abundance analytes. MindWalk carefully considers several key parameters in diagnostic reagent design, including target biology, assay format, test mechanisms, field utility, matrix effects, detection approach, and pairing requirements. Clone characterization is designed around the detection format and analytical performance requirements of the assay, with a goal of advancing antibodies that are fit-for-purpose in the diagnostic workflow they will anchor.
MindWalk has extensive experience designing and delivering diagnostic discovery antibodies for a diversity of applications including lateral flow and ELISA assays, immunohistochemistry approaches, and flow cytometry or FACS. Selection criteria are built directly into the target analysis approach and immunogen design philosophy of any given diagnostic discovery campaign, significantly reducing the risk of off-target responses. Combined with MindWalk’s Rabbit B cell Select® technology, our diagnostic discovery approach is designed to deliver detection antibodies in as little as 3 months, depending on project scope and technical requirements, supporting expedited downstream kit development and streamlined production timelines.
Antibody discovery programs generate candidates that need to be produced, characterized, and validated before they can advance.
The quality of that production step directly determines what can be learned from downstream assays and how confidently teams can act on the results. Molecular cloning, transient transfection, expression, protein purification, yield, purity, aggregation, endotoxin levels, and concentration all influence the reliability of the next decision.
MindWalk supports recombinant antibody and protein production for antibody discovery and development programs across the formats and scales each stage requires. Transient expression in HEK293 and CHO systems supports rapid turnaround for early candidate evaluation, producing material for binding characterization, functional screening, and structural studies without the timelines of stable cell line development.
For programs requiring higher yield, extended production runs, or material destined for in vivo studies, stable expression and scale-up pathways are available within the same program framework.
Affinity capture, ion exchange, and size exclusion steps are selected and combined based on antibody format, host cell system, and the purity requirements of the assay or study the material will support. Final production lots can be characterized for purity, aggregation, endotoxin levels, and concentration before release.
Characterization data can be incorporated into the program record within LensAI™ alongside discovery and functional data, helping teams evaluate candidate performance with greater continuity.
For programs producing immunization antigens, assay reference standards, or bioanalytical reagent material, production quality is treated as a scientific requirement that governs downstream data quality.
LensAI™, powered by HYFT technology, supports lab programs by connecting experimental results with biological context earlier in discovery. For antibody discovery and development programs, data from B cell clones, hybridoma panels, binding assays, functional screens, sequencing workflows, and characterization studies can be brought into a shared analytical environment as the program advances.
This helps broaden what teams can learn from lab-generated data. Instead of evaluating candidates only through isolated assay outputs, teams can connect sequence, structure, function, literature, and program-specific data to better understand target biology, candidate behavior, epitope relationships, and development considerations.
LensAI™, powered by HYFT Technology, supports a broad range of antibody discovery and development applications, including:
• Target Profiling
• Off-target and Cross-reactivity Analysis
• Antigen Design
• Epitope Prediction
• Epitope Specificity Analysis
• Protein Structure Prediction
• Molecular Dynamics Applications
• Epitope Mapping
• Affinity Prediction
• Paratyping
• Developability Assessment
• Immunogenicity Screening
• Hit Expansion
• Humanization
• Binding Affinity
• pH Selectivity
For complex discovery programs, these applications can help teams evaluate candidates with more context across biological relevance, functional activity, epitope behavior, developability, and downstream format fit.
Antibody programs generate rich, multi-dimensional data—across sequences, structures, assays, mechanisms, and program history. ReefIQ is the context layer that turns biologics program data into connected biological context AI can reason over. Powered by HYFT® technology, it delivers two essential functions: data orchestration, connecting the files, sources, teams, and workflows that discovery programs depend on; and a Bio-Native context layer, linking that data to biological relationships spanning sequence, structure, function, mechanism, pathway, and literature.
For antibody discovery and development, that connected context matters at every stage. Target analysis draws on broader relational biology. Lead evaluation is informed by structural and functional evidence in context. And knowledge compounds—each result, design decision, and assay output adds to a substrate that becomes more useful over time. That includes programs that didn't advance and deprioritized work, which often hold the most instructive context for what comes next.
ReefIQ sits beneath LensAI™ and client-selected AI models, providing the biological grounding that helps make AI reasoning across antibody programs more informed, connected and durable over time.
Work 1:1 directly with a team of scientific and technology experts. The blending of these disciplines creates a working model where biological interpretation, computational analysis, and experimental decision-making happen together, not sequentially. When a hit panel requires triage, when functional and binding kinetics data must be critically analyzed, or when a question spans biological and analytical dimensions simultaneously, integrated expertise in real time compresses the decision cycle.
Science and technology experts are engaged on your program for its full duration, becoming an extension of your labs and team. That continuity matters: the scientist who designed your immunization strategy is the same scientist interpreting your functional screening data and contributing to your lead nomination decision. This model is not incidental to the outcomes MindWalk delivers. It was designed with intention to be structurally responsible for them.
MindWalk supports antibody discovery and development for complex targets across therapeutic antibody programs, anti-idiotypic antibody development, anti-drug antibody solutions, and diagnostic antibody applications. More than 20 client-owned molecules advanced to the clinic through MindWalk’s wet lab discovery capabilities, reflecting the experience and breadth of a discovery model built for challenging biology, difficult epitopes, novel formats, and target classes that have resisted conventional approaches.
That proven wet lab foundation is now extended by the BioIntelligence Ecosystem, the LensAI™ platform powered by HYFT Technology, and a 1:1 expert engagement model, all built on an AI and data foundation that connects experimental results, sequence and structure data, functional activity, developability attributes, and biological context. This integrated foundation designed to help partners build stronger evidence packages, make better candidate decisions, and advance complex antibody programs with greater confidence.
Every antibody discovery and development program begins with a conversation about the molecule—what it is, what's been tried, and what success looks like for your team. Whether you're at the earliest stages of target assessment or need a specialized reagent package for a clinical-stage program, MindWalk brings the scientific depth, platform flexibility, and biointelligence infrastructure to help move it forward.